Published April 2, 2025 1 min read

# A shingles vaccine linked to about 20% lower dementia risk

## The short version

A Welsh natural experiment tied shingles vaccination to about 20 percent fewer new dementia diagnoses over seven years, or roughly 3.5 fewer cases per 100 people. A later split suggested carriers benefited too. Get the vaccine for shingles; treat the dementia signal as a bonus, not proof of prevention.

By the OutliveAPOE4 editorial team. [How we research & source](/methodology).

A Nature paper published on April 2, 2025 used a real-world quirk to get close to a randomized result. Wales rolled out its shingles vaccine with a hard birthdate cutoff: people born on or after September 2, 1933 were eligible, those born just before were not. People on either side of that line are otherwise alike, so comparing them (a regression-discontinuity design) sidesteps the usual problem that people who get vaccinated tend to be healthier to begin with.

A natural experiment can strengthen a causal case without becoming a clinical trial. Our [shingles-vaccine evidence review](/topics/shingles-vaccine-and-dementia-risk) walks through that distinction, and the [study-reading primer](/topics/reading-a-study-like-a-skeptic) is the practical framework for interpreting the next headline.

The finding: over **7 years**, vaccination was associated with a **20% relative reduction** in new dementia diagnoses, which works out to about **3.5 fewer cases per 100 people** in absolute terms. The effect was stronger in women.

Why this matters for a carrier: a later genotype-stratified analysis found carriers appeared to benefit too. And this is a cheap, low-regret, already-recommended vaccine, so the downside of acting on it is small.

The honest caveat: this is still a natural experiment, not a randomized dementia-prevention trial. The design is unusually strong for observational work, but it cannot fully close the gap to proof.

We unpack it in the deep dive on [the shingles vaccine and dementia risk](/topics/shingles-vaccine-and-dementia-risk), and on [reading a study like a skeptic](/topics/reading-a-study-like-a-skeptic) for why this design is convincing. Primary source: Nature, 2025. This is education, not medical advice.

## Source & references

1.  [Nature, 2025](https://www.nature.com/articles/s41586-025-08800-x)

## Related deep dives

-   [The Shingles Vaccine and Dementia: A Surprising Prevention Signal for APOE4 Carriers Vaccinated adults developed measurably less dementia in two strong natural experiments. For an APOE4 carrier, it may be a cheap, low-regret lever you are already due for.](/topics/shingles-vaccine-and-dementia-risk)
-   [Reading a study like a skeptic: a carrier’s media-literacy guide APOE4 headlines swing from "cure" to "doom" weekly. A practical toolkit for reading health studies and news so you can tell real signal from hype, and act on the right things.](/topics/reading-a-study-like-a-skeptic)
-   [HSV-1, cold sores, and Alzheimer’s risk in APOE4 carriers The cold-sore virus interacts with APOE4 specifically, raising Alzheimer's odds. Carriers ask if antivirals help. A 2026 randomized trial finally tested it. Here is the honest answer.](/topics/hsv1-cold-sores-and-alzheimers)